peptide mapping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Prognosis == With treatment, the majority of people with BPD can find relief from distressing symptoms and achieve remission, defined as a consistent relief from symptoms for at least two years. Remission rates are about 50–70% over five years. The remission rate is estimated to be around 50% at ten years, with 93% of people being able to achieve a two-year remission and 86% achieving at least a four-year remission, with a 30% risk of relapse over 10 years. Patient personality can play an important role during the therapeutic process, leading to better clinical outcomes. Recent research has shown that BPD patients undergoing dialectical behavior therapy (DBT) exhibit better clinical outcomes correlated with higher levels of the trait of agreeableness in the patient, compared to patients either low in agreeableness or not being treated with DBT. This association was mediated through the strength of a working alliance between patient and therapist; that is, more agreeable patients developed stronger working alliances with their therapists, which, in turn, led to better clinical outcomes. In addition to recovering from distressing symptoms, people with BPD can also achieve high levels of psychosocial functioning. A longitudinal study tracking the social and work abilities of participants with BPD found that six years after diagnosis, 56% of participants had good function in work and social environments, compared to 26% of participants when they were first diagnosed. Vocational achievement was generally more limited, even compared to those with other personality disorders.
However, the Smith government still professed loyalty to Elizabeth II, and accordingly the document reconstituted Rhodesia as a Commonwealth realm with Elizabeth as "Queen of Rhodesia". The new constitution created the concept of allegiance to the "Constitution of Rhodesia", and introduced the post of Officer Administering the Government, a viceregal figure empowered to sign passed legislation into law on behalf of the monarch if she did not appoint a Governor-General. The Rhodesian Cabinet waited in vain for Wilson's reply for the rest of 9 November and the next day. After briefly meeting Smith late on 10 November, Johnston warned Wilson that evening that the Rhodesians seemed poised to declare independence in the morning. The British prime minister tried repeatedly to call Smith, but did not get through until Smith was already chairing a Cabinet meeting on the independence issue around 08:00 Central Africa Time (06:00 in London) on 11 November. Wilson attempted to talk Smith out of unilateral action by telling him the status quo could continue, and the two argued inconclusively about the proposed Royal Commission. Returning to his Cabinet meeting, Smith reported the conversation to his ministers, and, after debating for a while, the Cabinet came to the conclusion that Wilson was simply attempting to buy more time and that there was no sign of actual progress. Smith asked if Rhodesia should declare its independence, and had each Cabinet minister answer in turn.
On 4 January 2023, it was reported that Brazil was seeking an Amazon summit between members of the Amazon Cooperation Treaty Organization (ACTO) and other non-members, which was reportedly well received by the ACTO countries. On 26 January, Lula invited French president Emmanuel Macron to attend the ACTO summit due to the French department of French Guiana location in the Amazon region.
== History == In 1982 Dr Alan Howard, together with his son Jon, formed the Howard Foundation into which all royalties and profits from worldwide sales of the Cambridge Diet and other intellectual property rights were paid. The Foundation currently focuses on biomedical research and philanthropy. The Foundation sponsors research into human nutrition and conferences on obesity, prostate cancer, creatine, and on macular carotenoids.
Sources: en.wikipedia.org
Apelin (also known as APLN) is a peptide that in humans is encoded by the APLN gene. Apelin is one of two endogenous ligands for the G-protein-coupled APJ receptor that is expressed at the surface of some cell types. It is widely expressed in various organs such as the heart, lung, kidney, liver, adipose tissue, gastrointestinal tract, brain, adrenal glands, endothelium, and human plasma.
Augustus is shown in his role of imperator, the commander of the army, as thoracatus —or commander-in-chief of the Roman army (literally, thorax-wearer)—meaning the statue should form part of a commemorative monument to his latest victories; he is in military clothing, carrying what may have been a spear or a consular baton, and raising his right hand in a rhetorical adlocutio pose, addressing the troops. The bas-reliefs on his armored cuirass have a complex allegorical and political agenda, alluding to diverse Roman deities, including Mars, god of war, as well as the personifications of the latest territories he conquered: Hispania, Gaul, Germania, Parthia (that had humiliated Crassus, and here appears in the act of returning the standards captured from his legions); at the top, the chariot of the Sun illuminates Augustus's deeds. The statue is an idealized image of Augustus showing a standard pose of a Roman orator and based on the 5th-century BC statue of the Spear Bearer or Doryphoros by the sculptor Polykleitos. The Doryphoros's contrapposto stance, creating diagonals between tense and relaxed limbs, a feature typical of classical sculpture, is adapted here. The pose of the statue's legs is similar to Doryphoros. The right leg is taut, while the left leg is relaxed, as if the statue is moving forward. The misidentification of the Doryphoros in the Roman period as representing the warrior Achilles made the model all the more appropriate for this image.
Some modern psychotherapy movements such as Re-evaluation Counseling encourage crying as beneficial to health and mental well-being. An insincere display of grief or dishonest remorse is sometimes called crocodile tears in reference to an Ancient Greek anecdote that crocodiles would pretend to weep while luring or devouring their prey. In addition, "crocodile tears syndrome" is a colloquialism for Bogorad's syndrome, an uncommon consequence of recovery from Bell's palsy in which faulty regeneration of the facial nerve causes people to shed tears while eating.
Sources: en.wikipedia.org
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known And Loved) and other publications, Alexander Shulgin lists thiobuscaline's dose range as 60 to 120 mg orally and its duration as about 8 hours. Its onset is about 1 hour. The effects of thiobuscaline have been reported to include a "benign and beautiful experience which never quite popped into anything psychedelic", subtle threshold effects, a vague awareness of something, being in a "wonderful place spiritually" but with "some dark edges", it being "pleasant, but certainly not psychedelic", and body discomfort. No clear hallucinogenic effects were described. Thiobuscaline is listed as being 4 times more potent as a psychoactive drug than mescaline. Thiobuscaline produced perpetual threshold psychoactive effects that did not further increase across a wide dose range of 35 to 120 mg orally. Shulgin described it as "always the simple and ephemeral catalyst of euphoria without substance and without body". In addition, he said that it could not easily be classified, for instance as a psychedelic or stimulant. Instead, Shulgin likened thiobuscaline to Ariadne (4C-D), which he noted had been called an "antidepressant". He hypothesized that thiobuscaline might be beneficial for treatment of depression in certain people in the exact same way as Ariadne.
== Etymology == Samaale, the last common ancestor of several Somali clans, is generally regarded as the source of the ethnonym Somali. Another theory is that the name is derived from the words soo and maal, which together mean "go" and "milk". This interpretation varies depending on region, with northern Somalis believing it means "camel's milk," and southern Somalis using the transliteration "sa maal", which refers to cow's milk. This is a reference to the pastoralism of the Somali people. Another proposed etymology is that the term Somali is derived from the Arabic ذوو مال, transliterated as dhawu māl and meaning "wealthy", again referring to Somali riches in livestock. The first written reference of the sobriquet Somali dates back to the early 15th century AD during the reign of Ethiopian Emperor Yeshaq I, who had one of his court officials compose a hymn celebrating a military victory over the Sultanate of Ifat. Simur was also an ancient Harari alias for the Somali people.
The three substrates of this enzyme are fluoroacetaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are fluoroacetic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is fluoroacetaldehyde:NAD+ oxidoreductase.
She has been affiliated with Brigham and Women's Hospital and is a member of the intramural faculty at the Koch Institute for Integrative Cancer Research. She served on the National Cancer Institute (NCI) Board of Scientific Advisors and co-led the first synthetic biomarker think tank at the NCI (SYNDICATE) with the late Sanjiv Gambhir. She also co-chaired the first AACR conference on Precision Prevention, Early Detection, and Interception of Cancer, and the annual Irwin M. Arias Symposium, a leading event in liver research.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.